Biogen Inc has agreed to pay US$22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients’ out-of-pocket drug costs as a means to pay them kickbacks to use its multiple sclerosis drugs.
Biogen to pay US$22 million to resolve US drug charity kickback probe
